Casi Pharmaceuticals Incorporated (NASDAQ:CASI) on Focus After Report of More Shorts

September 17, 2017 - By Winifred Garcia

 Casi Pharmaceuticals Incorporated (NASDAQ:CASI) on Focus After Report of More Shorts

Investors sentiment decreased to 0.88 in 2016 Q4. Its down 0.25, from 1.13 in 2016Q3. It is negative, as 3 investors sold CASI Pharmaceuticals Inc shares while 5 reduced holdings. 1 funds opened positions while 6 raised stakes. 2.22 million shares or 0.50% more from 2.21 million shares in 2016Q3 were reported.
Geode Management Limited Liability Corporation holds 38,700 shares. Everett Harris Comm Ca accumulated 10,002 shares. Blackrock Investment Mngmt Ltd has invested 0% of its portfolio in CASI Pharmaceuticals Inc (NASDAQ:CASI). National Bank & Trust Of America De has invested 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI). Blackrock Institutional Trust Na accumulated 225,650 shares. 55,090 are held by Raymond James Financial Services. Focused Wealth Mngmt invested 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI). California Public Employees Retirement Systems reported 0% stake. Vanguard Group Inc has 346,177 shares for 0% of their portfolio. Blackrock Advisors Limited Liability Company accumulated 0% or 7,740 shares. 528,447 are held by Wellington Shields Capital Limited Liability Company. Next Group has 0% invested in CASI Pharmaceuticals Inc (NASDAQ:CASI) for 2 shares. Wells Fargo Mn owns 98 shares for 0% of their portfolio. Northern Corporation holds 17,273 shares. Royal Financial Bank Of Canada has 0% invested in CASI Pharmaceuticals Inc (NASDAQ:CASI) for 19,589 shares.

The stock of Casi Pharmaceuticals Incorporated (NASDAQ:CASI) registered an increase of 5.09% in short interest. CASI’s total short interest was 74,300 shares in September as published by FINRA. Its up 5.09% from 70,700 shares, reported previously. With 9,200 shares average volume, it will take short sellers 8 days to cover their CASI’s short positions. The short interest to Casi Pharmaceuticals Incorporated’s float is 0.2%.

The stock increased 15.38% or $0.2 on September 15, reaching $1.5. About 355,943 shares traded or 704.23% up from the average. CASI Pharmaceuticals Inc (NASDAQ:CASI) has declined 17.65% since September 17, 2016 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $90.29 million. The Firm is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It currently has negative earnings. It operates through the development of targeted therapeutics for the treatment of cancer segment.

CASI Pharmaceuticals Inc (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel. As per Monday, August 14, the company rating was maintained by Maxim Group. Maxim Group initiated CASI Pharmaceuticals Inc (NASDAQ:CASI) on Thursday, September 22 with “Buy” rating. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, October 29 report.

More notable recent CASI Pharmaceuticals Inc (NASDAQ:CASI) news were published by: which released: “CASI Pharmaceuticals (CASI) Stock Spikes on EU Orphan Drug Designation” on October 14, 2015, also with their article: “CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global …” published on September 06, 2017, published: “CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In …” on August 16, 2016. More interesting news about CASI Pharmaceuticals Inc (NASDAQ:CASI) were released by: and their article: “CASI Pharmaceuticals’ Import Drug Registration Application For EVOMELA …” published on December 05, 2016 as well as‘s news article titled: “CASI Pharmaceuticals Reports First Quarter 2017 Financial Results” with publication date: May 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.